Urologic Oncology: Biomarkers and Targeted Therapies

Guest Editor:

Dr. Razvan Bardan
1. Department of Urology, Victor Babes University of Medicine and Pharmacy, 300041 Timişoara, Romania
2. Department of Urology, Clinical Emergency County Hospital, 300723 Timişoara, Romania

Deadline for manuscript submissions:
31 October 2024

Message from the Guest Editor

Urological malignancies, including prostate, urothelial, renal, and testicular cancers, pose significant challenges to patients due to their heterogeneity and variable responses to treatment. While traditional approaches can lead to suboptimal outcomes and unnecessary toxicity, new targeted therapies may represent a paradigm shift, offering personalised strategies tailored to the unique molecular profiles of tumors and patients.

This Special Issue aims to bring together the latest advances in the discovery, validation, and clinical application of prognostic approaches and monitoring biomarkers for uro-oncology targeted therapies. From genomic and proteomic signatures (taking advantage of recent advances in machine learning and artificial intelligence) to circulating tumor cells and imaging biomarkers, each contribution will provide new insights into treatment response prediction, prognosis estimation, and therapy resistance mechanisms.

mdpi.com/si/200039

Special Issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us